Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.
PLGA
long-acting depot
microparticles
semisolvent
solvent vapor
surface analysis
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
07 11 2022
07 11 2022
Historique:
pubmed:
28
9
2022
medline:
9
11
2022
entrez:
27
9
2022
Statut:
ppublish
Résumé
Poly(lactide-co-glycolide) (PLGA)-based microparticle formulations have been a mainstay of long-acting injectable drug delivery applications for decades. Despite a long history of use, tools and techniques to analyze and understand these formulations are still under development. Recently, a new characterization method was introduced known as the surface analysis after sequential semisolvent impact using sequential semisolvent vapors. The vapor-based technique is named, for convenience, surface analysis of (semisolvent) vapor impact (SAVI). In the SAVI method, discretely controlled quantities of selected organic semisolvents in the vapor phase were applied to PLGA microparticles to track particle morphological changes by laser scanning confocal microscopy. Subsequently, the morphological images were analyzed to calculate mean peak height (
Identifiants
pubmed: 36166409
doi: 10.1021/acs.molpharmaceut.2c00595
pmc: PMC9643650
mid: NIHMS1837033
doi:
Substances chimiques
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Polyglactin 910
34346-01-5
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4286-4298Subventions
Organisme : NIDA NIH HHS
ID : UG3 DA048774
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA048774
Pays : United States
Références
Arch Gen Psychiatry. 1973 Jun;28(6):784-91
pubmed: 4707988
Mol Pharm. 2020 Nov 2;17(11):4141-4151
pubmed: 32876463
J Pharm Sci. 2008 Jun;97(6):2022-35
pubmed: 17828755
Int J Pharm. 2008 Dec 8;364(2):298-327
pubmed: 18621492
Int J Pharm. 2021 Dec 15;610:121265
pubmed: 34748813
J Control Release. 2021 Aug 10;336:144-158
pubmed: 34126170
Mol Pharm. 2021 Jan 4;18(1):18-32
pubmed: 33331774
Int J Pharm. 2021 Apr 15;599:120450
pubmed: 33675924
Int J Pharm. 2016 Feb 10;498(1-2):274-82
pubmed: 26705156
Acta Crystallogr C Struct Chem. 2018 Mar 1;74(Pt 3):274-282
pubmed: 29504554
Acta Crystallogr E Crystallogr Commun. 2017 Jun 13;73(Pt 7):1013-1020
pubmed: 28775872
Int J Pharm. 2017 Mar 30;520(1-2):79-85
pubmed: 28153651
J Pharm Sci. 2018 Jan;107(1):353-361
pubmed: 29107048
Psychopharmacology (Berl). 2002 Feb;159(4):351-60
pubmed: 11823887
J Control Release. 2017 May 10;253:19-29
pubmed: 28284831
J Subst Abuse Treat. 2014 Aug;47(2):113-21
pubmed: 24854219
J Control Release. 2019 Apr 28;300:174-184
pubmed: 30853529
J Control Release. 2022 Oct;350:600-612
pubmed: 36057396
J Control Release. 2020 Apr 10;320:484-494
pubmed: 32027937
J Control Release. 2021 Jan 10;329:1150-1161
pubmed: 33148404
Int J Pharm. 2019 Jul 20;566:532-540
pubmed: 31181309
J Control Release. 2020 Sep 10;325:347-358
pubmed: 32645336
Addict Sci Clin Pract. 2020 Apr 22;15(1):15
pubmed: 32321570
Int J Pharm. 2021 Jun 1;602:120627
pubmed: 33915188
Int J Pharm. 2015 Nov 10;495(1):87-92
pubmed: 26319639
J Control Release. 2019 Jun 28;304:125-134
pubmed: 31071374
Int J Pharm. 2021 Jul 15;604:120738
pubmed: 34048931
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445587
Mol Pharm. 2020 May 4;17(5):1502-1515
pubmed: 32074448